Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) (SeliGIST)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04138381 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 24, 2019
Last Update Posted : March 27, 2023
|
Sponsor:
Grupo Espanol de Investigacion en Sarcomas
Information provided by (Responsible Party):
Grupo Espanol de Investigacion en Sarcomas
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | April 16, 2023 |
| Estimated Study Completion Date : | April 16, 2023 |